literature

HIV mutation literature information.

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: L234I

The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.

PMID: 32030406 2020 The Journal of antimicrobial chemotherapy

Abstract: METHODS: We used the WHO 2009 list to investigate the prevalence of NNRTI, NRTI and PI TDR, in treatment-naive HIV-1-infected patients, adding mutations E138A/G/K/Q/R, V106I, V108I, V179L, G190Q, H221Y, F227C/L/V, M230IDR, L234I, P236L and Y318F in RT.

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.

PMID: 32005262 2020 AIDS research and therapy

Result: This was followed by G190A/S/E/G that occurred in 55 (30.2%) of the patients, P236L mutation occurred in 2 (1.1%) and L234I that occurred in only 4 (2.2%) of the participants.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

PMID: 31976534 2020 The Journal of antimicrobial chemotherapy

Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus

Abstract: The following mutations were considered as resistance mutations: V106A/M, V108I, Y188L, G190S, F227C/L/V, M230I/L, L234I, P236L, K103N + Y181C, K103N + P225H and K103N + L100I.

Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia.

PMID: 32993693 2020 Retrovirology

Result: However, L234I; which is detected in one individual (1.96%), was recognized by the CPR tool only (Table 2).

Table: L234I

High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.

PMID: 30891603 2019 The Journal of antimicrobial chemotherapy

Result: Polymorphic mutations in the IN gene were frequently observed: L101I/M, TT124A/G/N and T125A/P/V (100%) were the most represented, followed by G134D/N/S and L234I/P/V (94.4%); T112A/E/I/T/V (83.3%), D167E/N (77.7%), K136R/Q/T (66.7%), I72V (50.0%), S255D/G/N (38.9%), N222K/T, T206S and T218I/L/S (33.3%); and I135V, I208L and S1

Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.

PMID: 30769200 2019 International journal of antimicrobial agents

Abstract: High-level DOR resistance was defined as detection of any of Y188L, M230L, G190E, V106A/M+F227L, and V106A/M+L234I.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

PMID: 30476106 2019 The Journal of antimicrobial chemotherapy

Abstract: We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

PMID: 30119633 2018 Retrovirology

Table: L234I

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

PMID: 29137637 2017 Virology journal